Literature DB >> 2546627

Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response.

L M Budel1, I P Touw, R Delwel, S C Clark, B Löwenberg.   

Abstract

Interleukin-3 (IL-3) and granulocyte-monocyte-colony-stimulating factor (GM-CSF) stimulate proliferation of human acute myeloid leukemia (AML) in vitro, although patterns of response among clinical cases are diverse. Whether regulatory abnormalities related to growth factor responses in human AML may establish the outgrowth of the neoplasm is unclear. We determined receptor numbers and affinity for IL-3 and GM-CSF on human AML cells using human recombinant IL-3 (rIL-3) and GM-CSF (rGM-CSF). In 13 of 15 cases of primary AML high-affinity (kd 26 to 414 pmol/L) receptors for IL-3 were demonstrable on the cells. The average numbers of IL-3 receptors ranged from 21 to 145 receptors per cell. Normal WBCs showed IL-3 receptors on their surface at similar densities. IL-3 receptor positivity often correlated with GM-CSF receptor positivity of AML; GM-CSF receptors were demonstrated on the cells of 11 of 15 cases, although average numbers of GM-CSF receptors were ten times greater. The in vitro response of the cells to exogenous IL-3 or GM-CSF was examined by measuring thymidine uptake. Because IL-3 and GM-CSF were potent inducers of DNA synthesis in vitro, apparently relatively few receptors are required to permit activation of growth. These experiments did not provide evidence for overexpression or increased receptor sensitivity as an explanation for AML growth. In a minority of cases, however, the cells were unable to respond to IL-3 (four of 15 cases) or GM-CSF (four of 15 cases) despite normal receptor availability on the cell surface.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546627

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Acute basophilic leukemia lacking basophil-specific antigens: the importance of cytokine receptor expression in differential diagnosis.

Authors:  Akihiko Yokohama; Norifumi Tsukamoto; Nahoko Hatsumi; Miwa Suto; Tohru Akiba; Hideki Uchiumi; Tadashi Maehara; Takafumi Matsushima; Masamitsu Karasawa; Hirokazu Murakami; Shougo Shinonome; Hirohisa Saito; Yoshihisa Nojima
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

Review 2.  Overview of cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy.

Authors:  Bin Bao; Aamir Ahmad; Asfar S Azmi; Shadan Ali; Fazlul H Sarkar
Journal:  Curr Protoc Pharmacol       Date:  2013-06

3.  Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.

Authors:  X Zhao; G J van Steenbrugge; F H Schröder
Journal:  Urol Res       Date:  1992

4.  Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML.

Authors:  Wei Du; Xu-E Li; Jared Sipple; Qishen Pang
Journal:  Blood       Date:  2011-02-17       Impact factor: 22.113

5.  A STUB1 ubiquitin ligase/CHIC2 protein complex negatively regulates the IL-3, IL-5, and GM-CSF cytokine receptor common β chain (CSF2RB) protein stability.

Authors:  Sebastian H J Koochaki; Mikołaj Słabicki; Ryan Lumpkin; Charles Zou; Roger Belizaire; Eric S Fischer; Benjamin L Ebert
Journal:  J Biol Chem       Date:  2022-09-12       Impact factor: 5.486

Review 6.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

7.  Inhibitory effects on in vitro cell growth of human urothelial tumor cell lines under the combined administration of hematopoietic growth factors and clinically relevant antineoplastic agents.

Authors:  T Block; U Treiber; B Geffken; M Vogel; A R Hanauske; F Schmid; R Hartung; R Busch
Journal:  Urol Res       Date:  1993-05

8.  Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.

Authors:  H H Gerhartz; R Marcus; A Delmer; H Zwierzina; T de Witte; A Jacobs; G Visiani; D Fiere; P Sonneveld; B Labar
Journal:  Infection       Date:  1992       Impact factor: 3.553

9.  Granulopoiesis inhibition in acute inflammation: comparative studies in healthy and leukaemic mice.

Authors:  M Hamood; F Corazza; P F Bluche; H El Teraifi; P Fondu
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

10.  Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms.

Authors:  Henrick Horita; Arthur E Frankel; Andrew Thorburn
Journal:  PLoS One       Date:  2008-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.